Archive — US — techcrunch
Not all cancer patients need chemo. Ataraxis AI raised $20M to fix that.
Ataraxis AI has raised $20.4 million to develop AI-based cancer treatment solutions. The New York startup aims to predict cancer outcomes and determine the necessity of chemotherapy, potentially saving costs and reducing side effects. Their first test for breast cancer will be launched for U.S. oncologists soon, leveraging technology that is 30% more accurate than current standards.
Key points
- Ataraxis AI raised $20.4 million in Series A funding to develop AI-based solutions in cancer treatment.
- The startup's technology can predict cancer treatment outcomes, helping to determine if chemotherapy is necessary.
- Launching their first commercial test for breast cancer in the coming months to U.S. oncologists.
- Their AI model is trained on millions of cancer cell images and offers 30% better accuracy than standard care.
- Big ambitions include impacting half of new cancer cases by 2030; aims to be an AI frontier lab for healthcare.
Why it matters
- The trend of using AI for cancer detection and treatment is on the rise, reflecting broader 2025 IT trends in healthcare.
- Significant funding influx in cancer startups shows investor confidence in AI's potential to personalize and improve treatment outcomes.
- AI-powered innovation in healthcare parallels advancements in drug discovery, with multiple startups successfully raising capital.
Ataraxis AI represents a significant shift in cancer care, aiming to personalize treatment through AI, which could reduce unnecessary chemotherapy and its side effects, aligning with current trends toward patient-centered healthcare.